JAMA Network Open:全球近30年来间皮瘤发病和死亡持续增长

2021-08-14 谈癌论健 谈癌论健

2021年8月11日,JAMA旗下子刊JAMA Network Open在线发表题为“Assessment of Global Trends in the Diagnosis of Mes

2021年8月11日,JAMA旗下子刊JAMA Network Open在线发表题为“Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017”(1990-2017年间皮瘤诊断全球趋势评估)的论著。浙江大学第一附属医院代志军教授和浙江省肿瘤医院/中国科学院肿瘤与基础医学研究所陈天辉教授为本研究的共同通讯作者。浙江大学第一附属医院为第一单位,西安交通大学第二附属医院为第二单位,翟真为第一作者(排名第一)。另外美国Celilo癌症研究中心、哈佛医学院、温州医科大学附属台州医院、暨南大学第一附属医院、美国奈特癌症研究所参与本研究。 一、背景 自然界中大约存在 400 种天然纤维, 其中 6 种矿物纤维被监管并统称为“石棉",即:角闪石纤维(青石棉、阳起石、透闪石、直闪石和铁闪石)和蛇纹石纤维(温石棉)。其余的约 400 种矿物纤维目前尚未得到监管。大量证据表明:所有形式的石棉对人类都有致癌作用,尤其是长期暴露于石棉与恶性胸膜间皮瘤的发病率紧密相关。  恶性胸膜间皮瘤是一种罕见但高度侵

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1729079, encodeId=b1671e290798b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 15 04:52:39 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734411, encodeId=a3e21e34411a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 25 23:52:39 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579832, encodeId=3df815e9832a7, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Aug 16 10:52:39 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036786, encodeId=70791036e86bd, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Aug 14 22:52:39 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2022-01-15 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1729079, encodeId=b1671e290798b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 15 04:52:39 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734411, encodeId=a3e21e34411a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 25 23:52:39 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579832, encodeId=3df815e9832a7, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Aug 16 10:52:39 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036786, encodeId=70791036e86bd, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Aug 14 22:52:39 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-25 canlab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1729079, encodeId=b1671e290798b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 15 04:52:39 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734411, encodeId=a3e21e34411a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 25 23:52:39 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579832, encodeId=3df815e9832a7, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Aug 16 10:52:39 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036786, encodeId=70791036e86bd, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Aug 14 22:52:39 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1729079, encodeId=b1671e290798b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 15 04:52:39 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734411, encodeId=a3e21e34411a3, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 25 23:52:39 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579832, encodeId=3df815e9832a7, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Aug 16 10:52:39 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036786, encodeId=70791036e86bd, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Aug 14 22:52:39 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-14 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

nintedanib对恶性胸膜间皮瘤的有效性

近日,欧洲研究人员发现,多靶点小分子抗癌药物nintedanib在临床前模型中显示出对人类恶性胸膜间皮瘤(一种致命的胸部肿瘤)生长的抑制作用

CLIN CANCER RES:吉西他滨联合免疫检查点抑制剂可以克服间皮瘤耐药

间皮瘤是一种侵袭性癌症,几乎没有有效的治疗方案。虽然免疫疗法可能会改善疾病的进程,但往往会出现耐药。因此,克服这种耐药并改善患者的预后至关重要。CLIN CANCER RES近期发表了一篇文章,研究研究免疫检查点抑制剂联合化疗对间皮瘤进行治疗。

Lancet respirat med:派姆单抗单药治疗晚期间皮瘤的疗效分析

派姆单抗在晚期MPM患者中展现出持续的抗肿瘤活性和可控的毒性,且不论PD-L1是阳性还是阴性

中国恶性胸膜间皮瘤临床诊疗指南(2021版),5分钟get要点!

间皮瘤是一种来源于胸膜或其他部位间皮细胞 的罕见肿瘤,其中来源于胸膜的约占81%,其他部 位包括腹膜、心包和睾丸鞘膜等 。

JAMA Psychiatry:英国肿瘤患者自杀风险研究

尽管绝对数字很低,但癌症患者自杀的风险增加是一个令人担忧的问题,在诊断后的前6个月风险增加表明肿瘤患者的心理支持存在较大空白

Lancet respir med:Tremelimumab(抗CTLA4单克隆抗体)联合durvalumab(抗PD-L1单克隆抗体)用于间皮瘤的疗效和安全性

Tremelimumab,抗CTLA4单克隆抗体,最初单独用于间皮瘤患者活性良好,但不能提高DETERMINE研究中一线或二线化疗失败的患者的总体存活率(与安慰剂对比)。现研究人员对Tremelimumab联合durvalumab(抗PD-L1单克隆抗体),作为一线或二线疗法,用于恶性间皮瘤的疗效和安全性进行评估。研究人员开展一开放性、非随机的临床II期试验,招募不可手术切除的胸膜或腹膜间皮瘤,予